StandardX Launches With £10m Seed Round to Create the Rare Isotopes Needed to Advance Medical and Fusion Innovation
StandardX, the UK-headquartered European deep tech company founded in 2025, led by Dr Richard Pearson, Dr Ross Allen, and the team, has raised £10m seed funding to build the world's first scalable isotope refinery to radically increase production of the rare isotopes that will enable the next century of innovation in medicine and energy. The round was led by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, UKI2S (the UK Innovation and Science Seed Fund, managed by Future Planet Capital), Brevan Howard Macro Venture and Geometry.
The Isotope Supply Problem.
Isotopes are critical to healthcare, energy, and other advanced industries, but global production remains constrained by ageing infrastructure, limited capacity, and a small number of facilities. The shortage is particularly acute in cancer diagnostics and treatment, with scarce medical isotopes delaying clinical trials for emerging therapies such as targeted alpha treatments.
StandardX’s Solution.
StandardX is developing an isotope refinery designed to provide a more reliable and scalable supply. Its proprietary accelerator platform can produce a broad range of isotopes at commercial scale, enabling distributed production closer to end users rather than relying on a small number of centralized facilities.
Initial production will focus on cancer diagnosis and treatment, serving both hospitals and drug developers. The company plans to supply its first isotopes to a medical research partner in 2027.
The same platform is designed to produce isotopes for other advanced industries, including tritium, a critical fuel for fusion energy. StandardX has already signed agreements with fusion developers to support future tritium production.
Founded by nuclear engineers Richard Pearson and Ross Allen, StandardX aims to build a more reliable and resilient European supply chain for critical isotopes.
Lise Rechsteiner, General Partner at Vsquared: “Radiopharma is approaching an extraordinary inflection point, but isotope supply simply hasn’t kept pace. StandardX is building a fundamentally flexible production platform that can move with the science, from the isotopes medicine needs today to those that will define the next generation of cancer treatment. We believe it can become critical infrastructure for the next era of radiopharma, and Richard and Ross have the rare technical expertise and ambition to build it. Being located in London puts StandardX at the heart of one of Europe’s leading ecosystems for cancer research and clinical trials.”
Theodore Mollinger, General Partner at EastX: “StandardX is tackling a supply problem that matters enormously today in medicine, while building a platform that could become critical infrastructure for fusion tomorrow. What makes the opportunity particularly compelling is the asymmetry: StandardX can build a valuable isotope business without relying on fusion timelines, but if fusion scales, tritium could become one of the defining industrial bottlenecks of the sector. With only a tiny global inventory today and substantial quantities ultimately required to fuel commercial fusion systems, we believe StandardX has the potential to play a critical role in securing that supply.”
𝐑𝐞𝐦𝐨𝐭𝐞 𝐇𝐢𝐫𝐞 𝐨𝐫 𝐁𝐮𝐢𝐥𝐝 𝐖𝐢𝐭𝐡 𝐔𝐬: 𝐁𝐮𝐢𝐥𝐝𝐰𝐞𝐫𝐤𝐬 helps technology companies build in India: two ways. Hire vetted remote engineers, product leaders, designers, and GTM professionals directly onto your team. Or partner with a proven development studio to design, build, and ship your product end-to-end. Learn More At: menlotimes.com/buildwerks
